Information Provided By: 
Fly News Breaks for June 18, 2015
BMRN
Jun 18, 2015 | 07:10 EDT
Deutsche Bank analyst Robyn Karnauskas raised her price target for BioMarin to $156 citing the positive Phase 2 trial results for BMN-111 in achondroplasia. Karnauskas now assumes an 85% probability of success for the drug. The analyst reiterates her view that with pipeline success, BioMarin's takeout value could be up to $300 per share. Her "blue sky" takeout value, which assumes 100% success to BioMarin’s entire pipeline, is up to $436 per share. Karnauskas reiterates a Buy rating on the stock.
News For BMRN From the Last 2 Days
